Eli Lilly is counting on psoriasis med Taltz to drive U.S. volume growth. But lately, that growth has stalled. New prescriptions for the next-gen med have stayed relatively flat over the last couple of months, Evercore ISI analyst Umer Raffat pointed out in a Friday note to clients. And new-to-brand prescriptions have actually declined.
More: As Taltz growth stalls, Lilly looks ahead to psoriatic arthritis expansion